School of Public Health, Levy Mwanawasa Medical University, Lusaka, Zambia
Zambia National Public Health Institute, Lusaka, Zambia.
BMJ Open. 2022 Nov 11;12(11):e066945. doi: 10.1136/bmjopen-2022-066945.
Zambia experienced a major cholera outbreak in 2017-2018, with more than 5905 cases reported countrywide, predominantly from the peri-urban slums of Lusaka city. The WHO recommends the use of oral cholera vaccines (OCVs) together with traditional control measures, including health promotion, provision of safe water and improving sanitation, in cholera endemic areas and during cholera outbreaks. In response to this outbreak, the Zambian government implemented the OVC campaign and administered the Euvichol-plus vaccine in the high-risk subdistricts of Lusaka. Although OCVs have been shown to be effective in preventing cholera infection in cholera endemic and outbreak settings, the effectiveness of the Euvichol-plus vaccine has not yet been evaluated in Zambia. This study aimed to determine the effectiveness of two doses of OCV administered during the 2017/2018 vaccination campaign.
We conducted a matched case-control study involving 79 cases and 316 controls following the mass vaccination campaign in the four subdistricts of Lusaka (Chawama, Chipata, Kanyama and Matero). Matching of controls was based on the place of residence, age and sex. Conditional logistic regression was used for analysis. Adjusted OR (AOR), 95% CI and vaccine effectiveness (1-AOR) for two doses of Euvichol-plus vaccine and any dose were estimated (p0.05).
The AOR vaccine effectiveness for two doses of Euvichol-plus OCV was 81.0% (95% CI 66.0% to 78.0%; p<0.01). Secondary analysis showed that vaccine effectiveness for any dose was 74.0% (95% CI 50.0% to 86.0%; p<0.01).
These findings show that two doses of Euvichol-plus OCV are effective in a cholera outbreak setting in Lusaka, Zambia. The findings also indicate that two doses are more effective than a single dose and thus support the use of two doses of the vaccine as part of an integrated intervention to cholera control during outbreaks.
2017-2018 年,赞比亚发生了大规模霍乱疫情,全国报告病例超过 5905 例,主要来自卢萨卡市的城市周边贫民窟。世界卫生组织建议在霍乱流行地区和霍乱疫情期间,使用口服霍乱疫苗(OCV)结合传统控制措施,包括健康促进、提供安全用水和改善卫生设施。针对此次疫情,赞比亚政府在卢萨卡高危分区实施了 OCV 运动,并接种了 Euvichol-plus 疫苗。尽管 OCV 已被证明在霍乱流行地区和疫情期间有效预防霍乱感染,但 Euvichol-plus 疫苗在赞比亚的有效性尚未得到评估。本研究旨在确定在 2017/2018 年疫苗接种运动中接种两剂 OCV 的效果。
我们在卢萨卡的四个分区(Chawama、Chipata、Kanyama 和 Matero)进行了一项匹配病例对照研究,共纳入 79 例病例和 316 例对照,随访大规模疫苗接种运动。对照匹配基于居住地、年龄和性别。采用条件逻辑回归进行分析。估计了两剂 Euvichol-plus 疫苗和任何一剂的调整优势比(AOR)、95%置信区间和疫苗有效性(1-AOR)(p<0.05)。
两剂 Euvichol-plus OCV 的 AOR 疫苗有效性为 81.0%(95%CI 66.0%至 78.0%;p<0.01)。二次分析显示,任何一剂的疫苗有效性为 74.0%(95%CI 50.0%至 86.0%;p<0.01)。
这些发现表明,两剂 Euvichol-plus OCV 在赞比亚卢萨卡的霍乱疫情中是有效的。这些发现还表明,两剂比一剂更有效,因此支持在疫情期间将两剂疫苗作为综合霍乱控制干预措施的一部分使用。